{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:38:59Z","timestamp":1793392739334,"version":"4.5.0"},"reference-count":35,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000261","name":"Multiple Sclerosis Society of Canada","doi-asserted-by":"publisher","award":["Postdoctoral Fellowship, PI: Anibal Chertcoff"],"award-info":[{"award-number":["Postdoctoral Fellowship, PI: Anibal Chertcoff"]}],"id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","award":["Trainee Award, Awardee: Anibal Chertcoff"],"award-info":[{"award-number":["Trainee Award, Awardee: Anibal Chertcoff"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-156363 and FDN-159934, PI: Tremlett"],"award-info":[{"award-number":["PJT-156363 and FDN-159934, PI: Tremlett"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Little is known about polypharmacy and multiple sclerosis (MS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To estimate polypharmacy prevalence in a population-based MS cohort and compare persons with\/without polypharmacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Using administrative and pharmacy data from Canada, we estimated polypharmacy prevalence (\u2a7e5 concurrent medications for &gt;30 consecutive days) in MS individuals in 2017. We compared the characteristics of persons with\/without polypharmacy and described the number of polypharmacy days, the most common medication classes contributing to polypharmacy and hyper-polypharmacy prevalence (\u2a7e10 medications).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 14,227 included individuals (75% women), mean age\u2009=\u200955.4 (standard deviation (SD): 13.2) years; 28% ( n\u2009=\u20093995) met criteria for polypharmacy (median polypharmacy days\u2009=\u2009273 (interquartile range (IQR): 120\u2013345)). Odds of polypharmacy were higher for women (adjusted odds ratio (aOR)\u2009=\u20091.14; 95% confidence intervals (CI):1.04\u20131.25), older individuals (aORs 50\u201364 years\u2009=\u20092.04; 95% CI:1.84\u20132.26; \u2a7e65\u2009years\u2009=\u20093.26; 95% CI: 2.92\u20133.63 vs. &lt;50\u2009years), those with more comorbidities (e.g. \u2a7e3 vs. none, aOR\u2009=\u20096.03; 95% CI: 5.05\u20137.22) and lower socioeconomic status (SES) (e.g. most (SES-Q1) vs. least deprived (SES-Q5) aOR\u2009=\u20091.64; 95% CI: 1.44\u20131.86). Medication classes most commonly contributing to polypharmacy were as follows: antidepressants (66% of polypharmacy days), antiepileptics (47%), and peptic ulcer drugs (41%). Antidepressants were most frequently co-prescribed with antiepileptics (34% of polypharmacy days) and peptic ulcer drugs (27%). Five percent of persons (716\/14,227) experienced hyper-polypharmacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>More than one in four MS persons met criteria for polypharmacy. The odds of polypharmacy were higher for women, older persons, and those with more comorbidities, but lower SES.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585221122207","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T12:00:24Z","timestamp":1666872024000},"page":"107-118","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":40,"title":["Polypharmacy and multiple sclerosis: A population-based study"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-6134","authenticated-orcid":false,"given":"Anibal","family":"Chertcoff","sequence":"first","affiliation":[{"name":"Faculty of Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, UBC Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8381-5253","authenticated-orcid":false,"given":"Huah Shin","family":"Ng","sequence":"additional","affiliation":[{"name":"Faculty of Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, UBC Hospital, Vancouver, BC, Canada\/College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, UBC Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinshan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Faculty of Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, UBC Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-2535","authenticated-orcid":false,"given":"Helen","family":"Tremlett","sequence":"additional","affiliation":[{"name":"Faculty of Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, UBC Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"issue":"1","key":"bibr1-13524585221122207","first-page":"32","volume":"100","author":"Halli-Tierney A","year":"2019","journal-title":"Am Fam Physician"},{"key":"bibr2-13524585221122207","unstructured":"World Health Organization. Medication safety in polypharmacy: Technical report. World Health Organization, 2019, https:\/\/apps.who.int\/iris\/handle\/10665\/325454"},{"key":"bibr3-13524585221122207","first-page":"1","volume":"347","author":"Hales CM","year":"2019","journal-title":"NCHS Data Brief"},{"key":"bibr4-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-52001-2.00023-6"},{"key":"bibr5-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.33"},{"key":"bibr6-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005347"},{"key":"bibr7-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.16473"},{"key":"bibr8-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211120"},{"key":"bibr9-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2014.02.013"},{"key":"bibr10-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40283-5"},{"key":"bibr11-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320983121"},{"key":"bibr12-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-017-0894-6"},{"key":"bibr13-13524585221122207","unstructured":"Health Canada, Government of Canada. Prescription drug insurance coverage, https:\/\/www.canada.ca\/en\/health-canada\/services\/health-care-system\/pharmaceuticals\/access-insurance-coverage-prescription-medicines.html (accessed December 2021)."},{"key":"bibr14-13524585221122207","unstructured":"Canadian Institute for Health Information, Statistics Canada. Health indicators 2013, https:\/\/www.cihi.ca\/sites\/default\/files\/document\/health-indicators-2013-en.pdf (accessed November 2021)."},{"key":"bibr15-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2021.1847085"},{"key":"bibr16-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000495"},{"key":"bibr17-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2"},{"key":"bibr18-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1195"},{"key":"bibr19-13524585221122207","doi-asserted-by":"publisher","DOI":"10.2165\/11319530-000000000-00000"},{"key":"bibr20-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03772.x"},{"key":"bibr21-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1720646"},{"key":"bibr22-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420969501"},{"key":"bibr23-13524585221122207","first-page":"317859","volume":"2015","author":"Beiske GAG","year":"2015","journal-title":"Mult Scler Int"},{"key":"bibr24-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1179\/1743132815Y.0000000036"},{"key":"bibr25-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4207"},{"key":"bibr26-13524585221122207","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00326"},{"key":"bibr27-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-019-0243-9"},{"key":"bibr28-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.02.010"},{"key":"bibr29-13524585221122207","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60240-2"},{"key":"bibr30-13524585221122207","first-page":"8809927","volume":"10","author":"Jaynes M","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"bibr31-13524585221122207","volume":"362","author":"Hayhoe B","year":"2018","journal-title":"BMJ"},{"key":"bibr32-13524585221122207","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2014-076"},{"key":"bibr33-13524585221122207","unstructured":"U.S. Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning, https:\/\/www.fda.gov\/media\/99761\/download (accessed October 2021)."},{"key":"bibr34-13524585221122207","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948030-00001"},{"key":"bibr35-13524585221122207","unstructured":"Department of Health & Social Care. Good for you, good for us, good for everybody, 2021, https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1019475\/good-for-you-good-for-us-good-for-everybody.pdf (accessed February 2022)."}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585221122207","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585221122207","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585221122207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:10:23Z","timestamp":1777695023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585221122207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/13524585221122207"],"URL":"https:\/\/doi.org\/10.1177\/13524585221122207","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}